TRAIL Fusion Polypeptide Targeting MUC16 for Pancreatic Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for pancreatic cancer are limited in effectiveness and often result in debilitating side effects, with a need for targeted treatments that can selectively induce cell death in tumor cells while minimizing toxicity to non-cancerous cells.
Innovation Solution
Development of fusion polypeptides comprising TRAIL trimers and targeting domains, specifically designed to bind to tumor cells expressing high levels of mesothelin and MUC16, enhancing apoptosis and reducing metastatic potential by anchoring TRAIL to the cell surface for more efficient receptor crosslinking.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for pancreatic cancer, then treatment coverage is provided, but effectiveness is limited and debilitating side effects occur
Solution Approach 1:
The therapy is segmented into two distinct functional domains: a targeting domain (mesothelin or MUC16) that selectively binds to tumor cells, and a TRAIL effector domain that induces apoptosis. This segmentation allows the targeting domain to direct the therapy specifically to cancer cells while the TRAIL domain executes the killing function, thereby improving effectiveness while minimizing side effects on non-cancerous cells.
Solution Approach 2:
The fusion polypeptide exhibits local quality by concentrating its apoptotic effect specifically at the location of tumor cells expressing mesothelin or MUC16. The targeting domain ensures localized binding to cancer cell surfaces, and the TRAIL domain then locally induces apoptosis only at these target sites, avoiding systemic toxicity to healthy tissues.
2Reliability
If TRAIL is anchored to the cell surface for efficient receptor crosslinking, then apoptosis enhancement is achieved, but device complexity increases
Solution Approach 1:
The invention merges the targeting function and the apoptotic effector function into a single fusion polypeptide molecule. The targeting domain (mesothelin or MUC16) is covalently linked to the TRAIL effector domain, creating a unified structure that simultaneously provides tumor cell recognition and apoptosis induction capabilities. This merging simplifies the overall therapeutic approach compared to using separate targeting and effector molecules.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion polypeptides, such as Meso-TR3, demonstrate enhanced killing capacity and selectivity for MUC16-positive tumor cells, achieving significant apoptosis and reduced tumor burden with minimal impact on non-target cells, as evidenced by in vitro and in vivo studies.
Implementation Method 1
Membrane-bound MUC16 binds to native mesothelin with high affinity
Implementation Method 2
TNF-related apoptosis-inducing ligand (TRAIL) has been shown to exhibit potent apoptotic activity against tumor cells
Data Source
AI summary
Fusion polypeptides comprising a TRAIL trimer and a targeting domain are disclosed. The targeting domain can be, in some embodiments, a sequence that binds MUC16, which is prevalent on some tumor cells such as pancreatic and ovarian tumor cells. A sequence that binds MUC 16 can be mesothelin or a MUC16-binding fragment thereof, such as amino acids 1-64 of mesothelin. A fusion polypeptide of the present teachings can induce apoptosis in a target cell such as a MUC16-expressing cancer cell. Also disclosed are nucleic acids encoding the fusion polypeptides, and methods of use of the fusion polypeptides and nucleic acids.